Recursion Launches Valence Labs at ICML with a Commitment to Open Science Including $1 Million in Academic Scholarships
26 juil. 2023 18h58 HE
|
Recursion Pharmaceuticals
SALT LAKE CITY, July 26, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today launched Valence Labs at...
Mustang Bio Announces Final Results from Follicular Lymphoma Cohort of Single-Institution Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR T Therapy
15 juin 2023 16h01 HE
|
Mustang Bio, Inc.
10 out of 20 patients remain in complete remission for more than a year 95% overall response rate (ORR) and 80% complete response (CR) rate across all patients; 100% ORR and 91% CR with higher dose...
Mustang Bio Announces Upcoming Presentations of Clinical Data from Phase 1/2 Trial of MB-106, a CD20-Targeted Autologous CAR T Cell Therapy
11 mai 2023 16h03 HE
|
Mustang Bio, Inc.
Data from Waldenstrom macroglobulinemia cohort selected for poster presentation at EHA2023 Outpatient treatment of follicular lymphoma selected for oral presentation at ICML WORCESTER, Mass., May ...
Innate Pharma présente des données préliminaires de l'essai TELLOMAK montrant une réponse clinique avec lacutamab dans le mycosis fungoides
22 juin 2021 07h00 HE
|
INNATE PHARMA
Marseille, 22 juin 2021 (GLOBE NEWSWIRE) -- Les premières données cliniques de TELLOMAK établissent la sécurité de lacutamab, des réponses cliniques ainsi qu’une amélioration au niveau de la peau...
Innate Pharma presents preliminary data from TELLOMAK trial showing clinical response for lacutamab in mycosis fungoides
22 juin 2021 07h00 HE
|
INNATE PHARMA
Marseille, June 22, 2021 (GLOBE NEWSWIRE) -- First data set from TELLOMAK establishes safety, clinical responses and skin improvement in patients with mycosis fungoides that express KIR3DL2 Data...
BeiGene Announces Clinical Data on Zanubrutinib to Be Presented at the 15th International Conference on Malignant Lymphoma (ICML)
12 juin 2019 04h00 HE
|
BeiGene, LTD.
CAMBRIDGE, Mass. and BEIJING, China, June 12, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...